Proceedings of the 2011 Santa Fe Bone Symposium

Journal of Clinical Densitometry

Volumn 15, Issue 1, 2012, Pages 1-20

  Lewiecki, E Michael ^a   Bilezikian, John P ^b   Jankowski, Lawrence G ^c   McCloskey, Eugene V ^d   Miller, Paul D ^e   Morgan, Sarah L ^f   Orwoll, Eric S ^g   Potts, John T ^h  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^b Columbia University ^*  (United States)

^c ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e Health Sciences Center and Colorado Center for Bone Research   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Denosumab; Emerging; FRAX; New; Osteoporosis; Safety; Treatment

Indexed keywords

ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; CATHEPSIN K INHIBITOR; CLODRONIC ACID; CREATININE; DENOSUMAB; ETIDRONIC ACID; ODANACATIB; ONO 5334; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SEROTONIN; UNCLASSIFIED DRUG; VITAMIN D; WNT PROTEIN; ZOLEDRONIC ACID;

BODY MASS; BONE DENSITOMETRY; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE SCINTISCANNING; BONE TURNOVER; CELLULITIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ECZEMA; ESOPHAGUS CANCER; FEMUR FRACTURE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; JAW OSTEONECROSIS; KIDNEY FUNCTION; LOW DRUG DOSE; METABOLIC BONE DISEASE; NONHUMAN; NUTRITION; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYMPOSIUM; VITAMIN SUPPLEMENTATION; WRIST FRACTURE;

ABSORPTIOMETRY, PHOTON; BONE DISEASES, METABOLIC; FEMALE; FRACTURES, BONE; HUMANS; MALE; NEW MEXICO; OSTEOPOROSIS;

EID: 84856356823     PISSN: 10946950     EISSN: 15590747     Source Type: Journal    
DOI: 10.1016/j.jocd.2011.11.004     Document Type: Review

References (173)

1. Lewiecki E.M., Baim S., Bilezikian J.P., et al. 2008 Santa Fe bone symposium: update on osteoporosis. J Clin Densitom 2009, 12(2):135-157.
2. Lewiecki E.M., Bilezikian J.P., Cooper C., et al. Proceedings of the Eighth Annual Santa Fe bone symposium, August 3-4, 2007. J Clin Densitom 2008, 11(2):313-324.
3. Lewiecki E.M. Proceedings of the Santa Fe bone symposium 2006. Womens Health 2006, 2(6):825-828.
4. Lewiecki E.M., Bilezikian J.P., Laster A.J., et al. 2009 Santa Fe bone symposium. J Clin Densitom 2010, 13(1):1-9.
5. Lewiecki E.M., Bilezikian J.P., Khosla S., et al. Osteoporosis update from the 2010 Santa Fe bone symposium. J Clin Densitom 2010, 14(1):1-21.
6. Lewiecki E.M., Bilezikian J.P., Miller P.D., et al. Highlights from the 2009 Santa Fe bone symposium 2009, Osteoporosis Foundation of New Mexico, Available at:, Accessed August 25, 2011. http://www.2009santafebonesymposium.com/downloads/2009-Santa-Fe-Bone-Newsletter.pdf.
7. Lewiecki E.M., Bilezikian J.P., Khosla S., et al. Highlights from the 2010 Santa Fe bone symposium 2010, Osteoporosis Foundation of New Mexico, Available at:, Accessed August 25, 2011. http://santafebonesymposium.squarespace.com/storage/assets/2010_Santa_Fe_Bone.pdf.
8. Lewiecki E.M., Bilezikian J.P., Khosla S., et al. 2010 Santa Fe bone symposium 2010, Osteoporosis Foundation of New Mexico, Available at:, Accessed August 25, 2011. http://www.2010santafebonesymposium.com/.
9. Lewiecki E.M., Bilezikian J.P., Miller P.D., et al. Santa Fe bone symposium 2009, Osteoporosis Foundation of New Mexico, Available at:, Accessed August 25, 2011. http://www.2009santafebonesymposium.com/.
10. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423(6937):337-342.
11. Vega D., Maalouf N.M., Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92(12):4514-4521.
12. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007, 22:1832-1841.
13. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354(8):821-831.
14. Miller P.D., Wagman R.B., Peacock M., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 2011, 96(2):394-402.
15. Bilezikian J.P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009, 122(2 Suppl):S14-S21.
16. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43(2):222-229.
17. Seeman E., Libanati C., Austin M., et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy. J Bone Miner Res 2011, 26.
18. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
19. Bone H.G., Chapurlat R., Libanati C., et al. Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis. J Bone Miner Res 2011, 26(Suppl 1):S22.
20. Reid I.R., Miller P.D., Brown J.P., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25(10):2256-2265.
21. Brown J.P., Dempster D.W., Ding B., et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res 2011, 26(11):2737-2744.
22. Stoch S.A., Wagner J.A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 2008, 83(1):172-176.
23. Pennypacker B., Shea M., Liu Q., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009, 44(2):199-207.
24. Bone H.G., McClung M.R., Roux C., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25(5):937-947.
25. Costa A.G., Cusano N.E., Silva B.C., et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011, 7(8):447-456.
26. Eastell R., Nagase S., Ohyama M., et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J Bone Miner Res 2011, 26(6):1303-1312.
27. Dobnig H., Turner R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997, 138(11):4607-4612.
28. Gallagher J.C., Genant H.K., Crans G.G., et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005, 90(3):1583-1587.
29. McClung M.R., San M.J., Miller P.D., et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005, 165(15):1762-1768.
30. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007, 146(5):326-339.
31. Bilezikian J.P. Treatment with parathyroid hormone (PTH) for osteoporosis: novel methods and benefits. JCRMM 2011, 2(1):6-13.
32. Fitzpatrick L.A., Dabrowski C.E., Cicconetti G., et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011, 96(8):2441-2449.
33. Rankin W., Grill V., Martin T.J. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997, 80(8 Suppl):1564-1571.
34. Horwitz M.J., Tedesco M.B., Garcia-Ocana A., et al. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 2010, 95(3):1279-1287.
35. O'Dea L. 2010 BA058, a novel analog of human parathyroid hormone-related peptide (PTHrP), induces a dose-dependent increase in BMD without the dose-limiting hypercalcemia of teriparatide: results of a randomized, placebo-controlled Phase 2 study. 14th International Congress of Endocrinology, Kyoto, Japan. Abstract No. O4-2.
36. Cosman F., Lane N.E., Bolognese M.A., et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010, 95(1):151-158.
37. Cusano N.E., Bilezikian J.P. Combination antiresorptive and osteoanabolic therapy for osteoporosis: we are not there yet. Curr Med Res Opin 2011, 27(9):1705-1707.
38. Kubota T., Michigami T., Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab 2009, 27(3):265-271.
39. Hoeppner L.H., Secreto F.J., Westendorf J.J. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 2009, 13(4):485-496.
40. Li X., Ominsky M.S., Warmington K.S., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24(4):578-588.
41. Richards J.B., Papaioannou A., Adachi J.D., et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167(2):188-194.
42. Yadav V.K., Ryu J.H., Suda N., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135(5):825-837.
43. Yadav V.K., Balaji S., Suresh P.S., et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010, 16(3):308-312.
44. Ducy P. 5-HT and bone biology. Curr Opin Pharmacol 2011, 11(1):34-38.
45. Goltzman D. LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res 2011, 26(9):1997-2001.
46. Cui Y., Niziolek P.J., MacDonald B.T., et al. Lrp5 functions in bone to regulate bone mass. Nat Med 2011, 17(6):684-691.
47. Wahner H.W., Dunn W.L., Brown M.L., et al. Comparison of dual-energy X-ray absorptiometry and dual photon absorptiometry for bone mineral measurements of the lumbar spine. Mayo Clin Proc 1988, 63:1075-1084.
48. Cullum I.D., Ell P.J., Ryder J.P. X-ray dual-photon absorptiometry: a new method for the measurement of bone density. Br J Radiol 1989, 62(739):587-592.
49. Lees B., Stevenson J.C. An evaluation of dual-energy X-ray absorptiometry and comparison with dual-photon absorptiometry. Osteoporos Int 1992, 2(3):146-152.
50. Kalender W.A. Effective dose values in bone mineral measurements by photon absorptiometry and computed tomography. Osteoporos Int 1992, 2(2):82-87.
51. Blake G.M., Naeem M., Boutros M. Comparison of effective dose to children and adults from dual X-ray absorptiometry examinations. Bone 2006, 38(6):935-942.
52. Svendsen O.L., Hassager C., Skodt V., Christiansen C. Impact of soft tissue on invivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study. JBone Miner Res 1995, 10(6):868-873.
53. Marshall D., Johnell O., Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312(7041):1254-1259.
54. Cummings S.R., Black D.M., Nevitt M.C., et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993, 341(8837):72-75.
55. Lotz J.C., Cheal E.J., Hayes W.C. Fracture prediction for the proximal femur using finite element models: part I-linear analysis. J Biomech Eng 1991, 113:353-360.
56. McCloskey E.V., Johansson H., Oden A., Kanis J.A. From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 2009, 7(3):77-83.
57. Hind K., Oldroyd B., Truscott J.G. Invivo precision of the GE Lunar iDXA densitometer for the measurement of total-body, lumbar spine, and femoral bone mineral density in adults. J Clin Densitom 2010, 13(4):413-417.
58. Shepherd J.A., Fan B., Lu Y., et al. Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int 2006, 17(9):1303-1308.
59. Blake G.M., Knapp K.M., Fogelman I. Dual X-ray absorptiometry: clinical evaluation of a new cone-beam system. Calcif Tissue Int 2005, 76(2):113-120.
60. Watts N.B. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int 2004, 15(11):847-854.
61. Lewiecki E.M., Binkley N., Petak S.M. DXA quality matters. J Clin Densitom 2006, 9(4):388-392.
62. Glüer C.C., Blake G., Lu Y., et al. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 1995, 5:262-270.
63. Shepherd J.A., Lu Y., Wilson K., et al. Cross-calibration and minimum precision standards for dual-energy X-ray absorptiometry: the 2005 ISCD Official Positions. J Clin Densitom 2006, 9(1):31-36.
64. Hangartner T.N. A study of the long-term precision of dual-energy X-ray absorptiometry bone densitometers and implications for the validity of the least-significant-change calculation. Osteoporos Int 2007, 18(4):513-523.
65. Leslie W.D. Factors affecting short-term bone density precision assessment and the effect on patient monitoring. J Bone Miner Res 2008, 23(2):199-204.
66. Leslie W.D., Moayyeri A. Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring. Osteoporos Int 2006, 17(11):1673-1680.
67. Frimeth J., Galiano E., Webster D. Some physical and clinical factors influencing the measurement of precision error, least significant change, and bone mineral density in dual-energy X-ray absorptiometry. J Clin Densitom 2010, 13(1):29-35.
68. Binkley N., Krueger D., Vallarta-Ast N. An overlying fat panniculus affects femur bone mass measurement. J Clin Densitom 2003, 6:199-204.
69. Baim S., Binkley N., Bilezikian J.P., et al. Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008, 11(1):75-91.
70. Pearson D., Cawte S.A. Long-term quality control of DXA: a comparison of Shewhart rules and Cusum charts. Osteoporos Int 1997, 7(4):338-343.
71. Lu Y., Mathur A.K., Blunt B.A., et al. Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res 1996, 11(5):626-637.
72. Hologic Inc. Hologic Discovery Operator's Manual 2011, Hologic Inc, New Bedford, MA.
73. CooperSurgical Inc. XR-600 Operator's Manual 2011, USA, CooperSurgical Inc, Fort Atkinson, WI.
74. GE Healthcare Lunar enCORE DXA Operator's Manual 2011, GE Healthcare Lunar, Madison, WI.
75. GE Healthcare Lunar DXA On-site PM Quality Record Checklist 2011, GE Healthcare Lunar, Madison, WI.
76. Fleisch H., Russell R.G., Francis M.D. Diphosphonates inhibit hydroxyapatite dissolution invitro and bone resorption in tissue culture and invivo. Science 1969, 165:1262-1264.
77. Bassett C.A., Donath A., Macagno F., et al. Diphosphonates in the treatment of myositis ossificans. Lancet 1969, 2(7625):845.
78. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61(9):1115-1117.
79. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62(5):527-534.
80. Marx R.E., Cillo J.E., Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007, 65(12):2397-2410.
81. Baim S., Miller P.D. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009, 24(4):561-574.
82. Glover S.J., Gall M., Schoenborn-Kellenberger O., et al. Establishinga reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res 2009, 24(3):389-397.
83. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
84. Grbic J.T., Black D.M., Lyles K.W., et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc 2010, 141(11):1365-1370.
85. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1489.
86. Ruggiero S.L., Dodson T.B., Assael L.A., et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009, 67(5 Suppl):2-12.
87. American Dental Association Council on Scientific Affairs Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006, 137(8):1144-1150.
88. Coleman R.E., Woodward E.J., Brown J.E., et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvent therapy in a randomized phase III trial for women with stage II/III breast cancer. Breast Cancer Res Treat 2011, 127(2):429-438.
89. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90(3):1294-1301.
90. Shane E., Burr D., Ebeling P.R., et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25(11):2267-2294.
91. AO Foundation Muller AO Classification of Fractures-Long Bones 2007, AO Foundation, Available at:, Accessed September 4, 2011. http://www2.aofoundation.org/AOFileServer/PortalFiles?FilePath=/Extranet/en/_att/wor/act/fracture_classif/mueller_ao_class.pdf.
92. Nieves J.W., Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 2010, 8(1):34-39.
93. Giusti A., Hamdy N.A., Dekkers O.M., et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48(5):966-971.
94. Puah K.L., Tan M.H. Bisphosphonate-associated atypical fracture of the femur: spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures-a case report. Acta Orthop 2011, 82(3):380-382.
95. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364(18):1728-1737.
96. US Food and Drug Administration FDA Drug Safety Communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures 2010, US Food and Drug Administration, Available at:, Accessed January 21, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm.
97. Nieves J.W., Bilezikian J.P., Lane J.M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21(3):399-408.
98. European Medicines Agency European Medicines Agency concludes class review of bisphosphonates and atypical fractures 2011, European Medicines Agency, Available at:, Accessed September 4, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/04/WC500105281.pdf.
99. Rizzoli R., Akesson K., Bouxsein M., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22(2):373-390.
100. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
101. Black DM, Reid IR, Boonen S, etal. 2011 The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. In press.
102. US Food and Drug Administration Update of safety review follow-up to the October 1, 2007. Early communication about the ongoing safety review of bisphosphonates 2008, U.S. Food and Drug Administration, Available at:, Accessed August 11, 2011. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm.
103. Wysowski D.K. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009, 360(1):89-90.
104. US Food and Drug Administration Oral Osteoporosis Drugs (bisphosphonates): Drug Safety Communication-Potential Increased Risk of Esophageal Cancer 2011, US Department of Health and Human Services, Available at:, Accessed September 10, 2011. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264087.htm.
105. US Food and Drug Administration FDA Drug Safety Communication: ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer 2011, US Department of Health and Human Services, Available at:, Accessed September 10, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm263320.htm.
106. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304(6):657-663.
107. Green J., Czanner G., Reeves G., et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
108. Pazianas M., Abrahamsen B. Safety of bisphosphonates. Bone 2011, 49(1):103-110.
109. Kanis J.A., Preston C.J., Yates A.J., et al. Effects of intravenous diphosphonates on renal function. Lancet 1983, 1(8337):1328.
110. Boonen S., Sellmeyer D.E., Lippuner K., et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008, 74(5):641-648.
111. Novartis Pharmaceuticals Corporation Zometa (zoledronic acid) Injection Prescribing Information 2011, Novartis Pharmaceuticals Corporation, Available at:, Accessed September 10, 2011. http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf.
112. Miller P.D. Intravenous bisphosphonate safety: the realities. Bone 2007, 41(5):S42-S43.
113. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007, 22(4):503-508.
114. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005, 20(12):2105-2115.
115. Miller P.D. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med 2009, 76(12):715-723.
116. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49(1):77-81.
117. Miller P.D. Is there a role for bisphosphonates in chronic kidney disease?. Semin Dial 2007, 20(3):186-190.
118. Miller P.D. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29(2):144-155.
119. Institute of Medicine Dietary reference intakes for calcium and vitamin D 2011, The National Academies Press, Washington, DC.
120. Ross A.C., Manson J.E., Abrams S.A., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. JClin Endocrinol Metab 2011, 96(1):53-58.
121. Rosen C.J., Gallagher J.C. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom 2011, 14(2):79-84.
122. Priemel M., von D.C., Klatte T.O., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010, 25(2):305-312.
123. Heaney R.P., Davies K.M., Chen T.C., et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003, 77(1):204-210.
124. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293(18):2257-2264.
125. Binkley N., Lewiecki E.M. Vitamin D and common sense. J Clin Densitom 2011, 14(2):95-99.
126. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96(7):1911-1930.
127. Mangano K.M., Walsh S.J., Insogna K.L., et al. Calcium intake in the United States from dietary and supplemental sources across adult age groups: new estimates from the National Health and Nutrition Examination Survey 2003-2006. J Am Diet Assoc 2011, 111(5):687-695.
128. Bailey R.L., Dodd K.W., Goldman J.A., et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010, 140(4):817-822.
129. Bolland M.J., Barber P.A., Doughty R.N., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336(7638):262-266.
130. Hsia J., Heiss G., Ren H., et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007, 115(7):846-854.
131. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
132. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 2010, 95(3):1174-1181.
133. Wang L., Manson J.E., Song Y., Sesso H.D. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010, 152(5):315-323.
134. Lewis J.R., Calver J., Zhu K., et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. JBone Miner Res 2011, 26(1):35-41.
135. Bhakta M., Bruce C., Messika-Zeitoun D., et al. Oral calcium supplements do not affect the progression of aortic valve calcification or coronary artery calcification. J Am Board Fam Med 2009, 22(6):610-616.
136. Manson J.E., Allison M.A., Carr J.J., et al. Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative. Menopause 2010, 17(4):683-691.
137. Bockman R.S., Zapalowski C., Kiel D.P., Adler R.A. The challenges of the single micronutrient study: commentary on calcium supplements and cardiovascular events 2011, American Society for Bone and Mineral Research, Available at:, Accessed June 9, 2011. http://www.asbmr.org/About/detail.aspx%3Fcid%3D3c1575bc-86cb-49bf-b397-2c748fe86581.
138. Heller H.J., Greer L.G., Haynes S.D., et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women. J Clin Pharmacol 2000, 40(11):1237-1244.
139. Heller H.J., Stewart A., Haynes S., Pak C.Y. Pharmacokinetics of calcium absorption from two commercial calcium supplements. J Clin Pharmacol 1999, 39(11):1151-1154.
140. Heaney R.P., Dowell M.S., Bierman J., et al. Absorbability and cost effectiveness in calcium supplementation. J Am Coll Nutr 2001, 20(3):239-246.
141. Heaney R.P., Dowell M.S., Barger-Lux M.J. Absorption of calcium as the carbonate and citrate salts, with some observations on method. Osteoporos Int 1999, 9(1):19-23.
142. O'Connell M.B., Madden D.M., Murray A.M., et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005, 118(7):778-781.
143. Recker R.R. Calcium absorption and achlorhydria. N Engl J Med 1985, 313(2):70-73.
144. Brener Z.Z., Winchester J.F., Salman H., Bergman M. Nephrolithiasis: evaluation and management. South Med J 2011, 104(2):133-139.
145. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354(7):669-683.
146. Curhan G.C., Willett W.C., Knight E.L., Stampfer M.J. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004, 164(8):885-891.
147. Curhan G.C., Willett W.C., Rimm E.B., Stampfer M.J. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993, 328(12):833-838.
148. Borghi L., Schianchi T., Meschi T., et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002, 346(2):77-84.
149. Heaney R.P. Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr 2008, 27(5):519-527.
150. Hopkins RB, Pullenayegum E, Goeree R, etal. 2011 Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int. In press.
151. Feldstein A.C., Nichols G., Orwoll E., et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005, 16(8):953-962.
152. Khosla S., Amin S., Orwoll E. Osteoporosis in men. Endocr Rev 2008, 29(4):441-464.
153. Lewis C.E., Ewing S.K., Taylor B.C., et al. Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 2007, 22(2):211-219.
154. De Laet C., Kanis J.A., Oden A., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005, 16(11):1330-1338.
155. Bouxsein M.L., Szulc P., Munoz F., et al. Contribution of trochanteric soft tissues to fall force estimates, the factor of risk, and prediction of hip fracture risk. J Bone Miner Res 2007, 22(6):825-831.
156. Nielson C.M., Marshall L.M., Adams A.L., et al. BMIand fracture risk in older men: the osteoporotic fractures in men study (MrOS). J Bone Miner Res 2011, 26(3):496-502.
157. Nielson C.M., Bouxsein M.L., Freitas S.S., et al. Trochanteric soft tissue thickness and hip fracture in older men. J Clin Endocrinol Metab 2009, 94(2):491-496.
158. Cawthon P.M., Ewing S.K., McCulloch C.E., et al. Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 2009, 24(10):1728-1735.
159. Cawthon P., Ewing S., Mackey D., et al. Change in hip bone mineral density (BMD) and risk of fractures in older men. J Bone Miner Res 2010, 25(Suppl 1):S314. (Abstract #SU0314).
160. Ensrud K.E., Taylor B.C., Paudel M.L., et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab 2009, 94(8):2773-2780.
161. Cauley J.A., Ewing S.K., Taylor B.C., et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density-the osteoporotic fractures in men study. J Clin Endocrinol Metab 2010, 95(9):4314-4323.
162. Jutberger H., Lorentzon M., Barrett-Connor E., et al. Smoking predicts incident fractures in elderly men: Mr OS Sweden. JBone Miner Res 2010, 25(5):1010-1016.
163. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. JClin Endocrinol Metab 2009, 94(2):335-339.
164. Kawai M., Modder U.I., Khosla S., Rosen C.J. Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov 2011, 10(2):141-156.
165. Albright F., Ellsworth R. Uncharted seas 1990, Kalmia Press, Portland, OR.
166. Potts J.T. Parathyroid hormone: past and present. J Endocrinol 2005, 187(3):311-325.
167. Lowe H., McMahon D.J., Rubin M.R., et al. Normocalcemic primary hyperparathyroidism: further characterization of a newclinical phenotype. J Clin Endocrinol Metab 2007, 92(8):3001-3005.
168. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357(9):905-916.
169. Ferrandon S., Feinstein T.N., Castro M., et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol 2009, 5(10):734-742.
170. Okazaki M., Ferrandon S., Vilardaga J.P., et al. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A 2008, 105(43):16525-16530.
171. Sackett D.L., Rosenberg W.M., Gray J.A., et al. Evidence based medicine: what it is and what it isn't. BMJ 1996, 312(7023):71-72.
172. Swiglo B.A., Murad M.H., Schunemann H.J., et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 2008, 93(3):666-673.
173. Lewiecki E.M., Binkley N. Evidence-based medicine, clinical practice guidelines, and common sense in the management of osteoporosis. Endocr Pract 2009, 24(10):1643-1646.